These divergent findings underscore the intricate interplay between anti-inflammatory pathways and tumor-specific biological contexts, highlighting the challenges posed by mechanistic complexity and interpatient heterogeneity in translating COX-2-targeted strategies into clinical benefit. The gene discussed is PTGS2; the disease is neoplasm.